| Literature DB >> 32867320 |
Sang Bong Lee1, Hyeonsoo Park2,3, Jae-Eon Lee2,4, Kil-Soo Kim2,5, Yong Hyun Jeon2,6.
Abstract
This study was conducted to monitor the macrophage infiltration of atopic dermatitis (AD)-like skin lesions and to evaluate the effects of anti-AD therapeutic agents in immunocompetent mice via optical reporter-gene-based molecular imaging. The enhanced firefly luciferase (effluc)-expressing macrophage cell line (Raw264.7/effluc) was intravenously introduced into mice with 2,4-dinitrochlorobenzene (DNCB)-induced AD, followed by bioluminescent imaging (BLI). After in vivo imaging, AD-like skin lesions were excised, and ex vivo imaging and Western blotting were conducted to determine the presence of infused macrophages. Finally, the therapeutic effect of dexamethasone (DEX), an AD-modulating agent, was evaluated via macrophage tracking. In vivo imaging with BLI revealed the migration of the reporter macrophages to DNCB-induced AD-like skin lesions on day 1 post-transfer. The greatest recruitment was observed on day 3, and a decline in BLI signal was observed on day 14. Notably, in vivo BLI clearly showed the inhibition of the reporter macrophage infiltration of DNCB-induced AD-like skin lesions by DEX, which was consistent with the reduced AD symptoms observed in DEX-treated mice. We successfully visualized the macrophage migration to DNCB-induced AD-like skin lesions, proving the feasibility of macrophage imaging for evaluating AD-regulating drugs in living organisms.Entities:
Keywords: atopic dermatitis; bioluminescence imaging (BLI); cell tracking; enhanced firefly luciferase gene (effluc); reporter macrophages
Mesh:
Substances:
Year: 2020 PMID: 32867320 PMCID: PMC7503337 DOI: 10.3390/ijms21176205
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Scheme for the in vivo tracking of the macrophage infiltration in dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD) using optical reporter-gene-based molecular imaging. Mice were anesthetized with 1%–2% isoflurane gas, and then the dorsal site of the mice was carefully shaved prior to DNCB application. Reporter macrophages were injected via the tail vein, and bioluminescence imaging (BLI) was performed with the optical imaging system.
Figure 2Expression of the enhanced firefly luciferase (effluc) gene as an optical reporter gene in Raw264.7 cells. (a) Western blot analysis showing the luciferase protein expression with anti-luciferase antibodies. (b) In vitro BLI in Raw264.7 and Raw264.7/effluc cells. (c) Quantification of the bioluminescence imaging signals. The experiments were performed at least in triplicate, and the bar graphs represent means ± SDs.
Figure 3In vivo optical imaging of the macrophage infiltration of dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD). (a) Experimental procedures for in vivo animal experiments. (b) Visualization of the macrophage cell migration to DNCB-induced AD-like lesions. AD mice received reporter macrophage cells via intravenous injection, and their migration to the AD-like lesions was monitored at the indicated times. (c) Quantification of the bioluminescence imaging (BLI) signals in AD lesions at indicated times. Inset with square dotted lines shows the BLI signals in AD-like lesions on day 14. (d) Ex vivo BLI for the detection of infiltrated reporter macrophages in AD on day 14. (e) Immunoblot analysis in excised AD-like and control skins with anti-luciferase antibodies for evaluation of the presence of infiltrated reporter macrophages in AD-like lesions. Each group consisted of four mice, and experiments were performed at least in triplicate. The values indicate means ± SDs.
Figure 4Effects of dexamethasone (DEX) on lipopolysaccharide (LPS)-stimulated reporter macrophages. Reporter macrophages were pre-treated with the indicated concentration of DEX for 1 h and then with LPS (1 μg/mL, 24 h). (a) Nitric oxide (NO) levels in respective reporter macrophages. Expression levels of the cytokines (b) TNF-α, (c) IL-6, and (d) IL-1β in the culture medium were determined by the enzyme-linked immunosorbent assay (ELISA). (e) Western blot analysis showing the expression levels of COX-2, p-AKT, and p-ERK in respective reporter macrophages. Values obtained from three individual experiment are expressed as the mean ± standard deviation (SD), *** p < 0.001
Figure 5In vivo assessment of the therapeutic effects of an atopic dermatitis (AD)-modulating agent using the macrophage tracking approach. (a) Protocols for in vivo animal experiments. (b) In vivo optical imaging of the macrophage migration into AD-like lesions in the vehicle- and dexamethasone (DEX)-treated mice. The dotted red circles indicate the AD-like lesions. (c) Quantification of the bioluminescence imaging (BLI) signals (vehicle and DEX) in AD-like lesions. (d) Photograph of AD mice. (e) Quantification of the BLI signals in excised AD-like lesions from each group. Values obtained from three individual experiment are expressed as the mean ± standard deviation (SD), * p < 0.05